Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P17813
UPID:
EGLN_HUMAN
Alternative names:
-
Alternative UPACC:
P17813; Q14248; Q14926; Q5T9C0
Background:
Endoglin is a crucial vascular endothelium glycoprotein, instrumental in angiogenesis regulation and maintaining adult vasculature structure. It facilitates endothelial cell migration, is essential for embryonic heart development and extraembryonic angiogenesis, and influences endothelial cell responses to blood flow. Endoglin's role in TGF-beta/BMP signaling, acting as a coreceptor, underscores its importance in vascular biology.
Therapeutic significance:
Linked to Telangiectasia, hereditary hemorrhagic, 1, Endoglin's mutations underscore its therapeutic potential. Understanding Endoglin's role could unveil new therapeutic strategies for vascular dysplasias, offering hope for managing hereditary hemorrhagic Telangiectasia and related vascular anomalies.